NVL-655
We are excited to report the results of this collaboration with Nuvalent at the 2022 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics: NVL-655 shows activity against lorlatinib-resistant ALK NSCLC experimental models harboring compound ALK resistance mutations.
